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Available online 4 April 2016This noninterventional, observational, postauthorization safety study (SP0942, NCT00771927) evaluated the
incidence of predeﬁned cardiovascular- (CV) and psychiatric-related treatment-emergent adverse events
(TEAEs), in patients with epilepsy and uncontrolled partial-onset seizures, when initiating adjunctive therapy
with lacosamide or another approved antiepileptic drug (AED) according to standard medical practice. Active
recording of predeﬁned TEAEs of interest took place at three-monthly recommended visits for up to 12 months.
Of 1004 patients who received at least one dose of adjunctive AEDs, 511 initially added lacosamide therapy, 493
added another AED, 69 were ≥65 years of age, and 72 took concomitant antiarrhythmic drugs. Patients in the
lacosamide cohort had a highermedian frequency of partial-onset seizures (6.0 versus 3.5per 28 days) despite tak-
ingmore concomitant AEDs (84.9% versus 66.9% took ≥2) at baseline. Patientswho added lacosamide took amodal
dose of 200mg/day over the treatment period (n=501), and 50.1% (256/511) completed 12months of treatment.
Fifty-one point nine percent (256/493) of patients who added another AED completed the study, with the most
commonly addedAEDbeing levetiracetam (28.4%). Four patients (0.8%) in each cohort, all b65 years of age, report-
ed predeﬁned CV-related TEAEs. None were considered serious or led to discontinuation. One event each of sinus
bradycardia (lacosamide), atrioventricular block ﬁrst degree (lacosamide), and syncope (other AED) were judged
to be treatment-related. Another patient in the other AED cohort reported bradycardia while taking concomitant
antiarrhythmic drugs. Predeﬁned psychiatric-related TEAEswere reported by 21 patients (4.1%) in the lacosamide
cohort and 27 patients (5.5%) in the other AED cohort. Depression was the most common to be treatment-related
(7/11 and 12/18 of patients reporting treatment-related psychiatric TEAEs, respectively). Serious psychiatric-
related TEAEs were reported by four patients who added lacosamide (two cases of depression, two of suicide
attempt) and one who added another AED (depression). Seven deaths occurred, all of which were considered
unrelated/unlikely related to study medication. This thorough evaluation revealed a low incidence of predeﬁned
CV- and psychiatric-related TEAEs in patients taking adjunctive AED therapy according to standard medical
practice. No speciﬁc safety concerns related to adjunctive lacosamide therapy were noted.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Lacosamide is a functionalized amino acidwith proven efﬁcacy as an
antiepileptic drug (AED). In Europe, lacosamide is currently approved as
an adjunctive therapy for the treatment of partial-onset seizures (POS)
in adult and adolescent (16–18 years of age) patients with epilepsy, at
dosages up to 400 mg/day (200 mg twice a day) [1]. Lacosamide is
approved in several other countries, including the United States, where
it is licensed for use as a monotherapy or adjunctive therapy in patients
(≥17 years of age) with POS [2].
Pharmacokinetic studies have shown lacosamide to have minimal
protein binding, high oral absorption, dose-proportional bioavailability,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Predeﬁned cardiovascular- and psychiatric-related treatment-emergent adverse events.
Cardiovasculara
Adams–Stokes syndrome AV block second degree Sinus bradycardia
AV block Syncope ECG PR prolongation
(201–209 ms)AV block complete Bradycardia
AV block ﬁrst degree Bradyarrhythmia
Psychiatrica
Depression Intentional self-injury Substance abuse
Major depression Self-injurious behavior Substance abuser
Depressed mood Self-injurious ideation Polysubstance dependence
Depression suicidal Poisoning deliberate Intentional drug misuse
Completed suicide Drug abuse Intentional overdose
Suicidal behavior Drug abuser Multiple drug overdose,
intentionalSuicidal ideation Drug dependence
Suicide attempt
AV, atrioventricular; ECG, electrocardiogram.
a Medical Dictionary for Regulatory Activities (MedDRA, Version 15.0) preferred terms.
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teractions [3,4]. Three Phase II/III, double-blind, randomized registration
trials conﬁrmed the safety and efﬁcacy of lacosamide inmore than 1300
patients with POS, each randomized to receive 200, 400, or 600 mg/day
lacosamide or placebo, to be taken adjunctive to one to three baseline
AEDs [5–7]. The treatment-emergent adverse events (TEAEs) most
frequently reported during the registration trials were central nervous
system- and gastrointestinal-associated. The most common drug-
related adverse events (AEs), namely dizziness andnausea, also showed
a relationship with dose [5–7]. Similar types of TEAEs were observed in
short-term studies of adjunctive lacosamide therapy via intravenous
administration, in long-term open-label studies for up to 8 years, and
when taken as monotherapy [8–13].
Cardiac conduction side effects are associatedwith the use of several
AEDs, particularly those that block sodium channels [14–17]. A small
dose-related increase in the PR interval has been observed in trials of
oral and intravenous lacosamide, with no signiﬁcant change in blood
pressure or QTc interval [11–13,18–20]. There have also been some
published reports of cardiac AEs in patients receiving lacosamide
[9,18,21–28].
Some AEDs have a known potential for recreational abuse [29–31].
While a few euphoria cases were reported during pharmacokinetic
and human abuse studies, overall, euphoriawas rarely (b1% of patients)
reported during the lacosamide development program [2,32].
Psychiatric conditions exist at a higher prevalence among patients
with epilepsy than in the general population, including depression, anx-
iety, and aggression disorders [33,34]. SomeAEDs have shown potential
associations with psychiatric AEs and behavioral changes [35–37].
Psychiatric-related AEs (such as depression) are commonly listed in
AED labeling, including that for lacosamide [1,2].
AEDs in general may increase the risk of suicidal thoughts or
behavior in patients taking these drugs for any indication. A class warn-
ing is in place and acknowledged in all AED product labeling [35,38–40];
however, the mechanism for this increased risk is unknown. The overall
efﬁcacy and safety of adjunctive lacosamide use for the treatment of un-
controlled POS was established in well-controlled clinical studies.
Postauthorization, noninterventional studies provide data which are
complementary to that obtained from randomized, placebo-controlled
studies, which are generally conducted in more optimized treatment
settings. Postauthorization, observational studies include patients with
diverse characteristics and comorbidities, reﬂective of the patient popu-
lationwho receive that medication in real-life, according to the product
label and summary of product characteristics. Flexible drug selection
and dosing reﬂects the standard medical care received by patients in
the real-world, where medical supervision may also be less intensive
than in controlled studies, and treatment decisions may be inﬂuenced
by additional factors. Patients in these studies may also have more
control over their own treatment, including care decisions and medica-
tion compliance. In this way, the lack of controlled factors during
postauthorization, noninterventional studies is of great beneﬁt, as the
results provide a ‘snap-shot’ on the effectiveness of medications in the
way that they are currently used in real-life. This observational,
postauthorization safety study (PASS) of lacosamide provides comple-
mentary data to that obtained during the three registration trials, and
was conducted as a commitment to the European Medicines Agency
to speciﬁcally assess the incidence of predeﬁned cardiovascular (CV)-
and psychiatric-related TEAEs in patients with uncontrolled POS who
use lacosamide in routine clinical practice.
2. Methods
2.1. Study design
This noninterventional PASS (SP0942, NCT00771927)was conducted
at 71 sites in France, Germany, the Netherlands, Spain, and the United
Kingdom. Patients were assigned to one of two cohorts based on thedecision to prescribe lacosamide or another AED, made by the treating
physician prior to enrollment and according to standard medical prac-
tice. Eligible patients were enrolled within 2 days of treatment initiation
in blocks of 10 per physician: ﬁve who added lacosamide and ﬁve who
added another AED. These patients formed the “lacosamide cohort”
and the “other AED cohort”, respectively. Treatment continued per
standard local medical practice for up to 12 months, allowing ﬂexible
treatment according to individual patient need and physician's
judgment. It was recommended that follow-up visits occurred at 3, 6,
9, and 12 months, with an additional safety visit 2 weeks after the end
of treatment if adjunctive treatment was discontinued before the end
of the study. A routine electrocardiogram (ECG) was conducted at each
study visit if part of the site's standard medical practice.
2.2. Patients
Patients aged 16 years or older with a diagnosis of epilepsy and
experiencing POS considered by the treating physician to be
uncontrolled on current therapy were assigned adjunctive AED
therapy. The study protocol was approved by an independent ethics
committee. All patients provided written consent and were treated
in accordance with local regulations and the Declaration of Helsinki.
2.3. Study variables
The primary safety variables for this study were the incidence of
predeﬁned CV- and psychiatric-related TEAEs (Table 1). Treatment-
emergent adverse events were deﬁned as AEs occurring during
treatment or within 30 days of the last dose. All AEs were reported
to or observed by the physician at every visit, with additional active
collection of predeﬁned CV- and psychiatric-related TEAEs using a
checklist. The recording physician also assessed the intensity and
relationship of each AE to the study treatment. Relationships of
“possible”, “probable”, or “highly probable”, or entries with missing
relationship data, were classiﬁed as drug-related. The intensity of each
TEAE was categorized based on the impact caused to routine activities
in daily life. Adverse events with missing intensity entries were
categorized as severe. Other safety variables included the overall
incidence of TEAEs and serious AEs (SAEs), and TEAEs leading to
discontinuation of the added AED.
The modal daily dose of lacosamide taken during the treatment
period was calculated for each patient. This was used to calculate
the overall mode of the modal daily doses in the lacosamide cohort.
Although not predeﬁned, several other variables were evaluated, if
captured as part of routine clinical practice: the occurrence of TEAEs,
changes in vital signs and body weight, the median percent change in
seizure frequency per 28 days from the 2-month retrospective baseline,
the Clinical Global Impression of Change questionnaire for the
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tion time (assessed using the Kaplan–Meier method).
2.4. Data analysis
Statistical summaries of the data employed descriptive statistics.
Based on a sample size of 500 patients per cohort, the probability of
observing at least one TEAE within a category of interest (i.e., CV- or
psychiatric-related) was 99.3%, assuming an overall incidence of
1.0% for the category of interest. All safety variables were summa-
rized using the safety set (SS), comprising all patients with baseline
characteristic data who received at least one dose of study treatment.
Two additional analyses were conducted on special patient
subgroups: those ≥65 years of age versus b65 years and those taking
concomitant antiarrhythmic medications (coded to one of the
following World Health Organization Anatomical Therapeutic
Chemical codes: C01B, C07, or C08D) versus those who were not
taking those medications.
3. Results
3.1. Patient disposition
Of the 1005 patients enrolled in the study, all but one (who did not
meet the entry criteria) constituted the SS. In total, 511 patients initiated
adjunctive lacosamide therapy at enrollment and formed the lacosamide
cohort, while 493 received another adjunctive AED and formed the other
AED cohort. Overall, 512/1005 patients (50.9%) completed the study, 256
patients per cohort (Fig. 1).
In the lacosamide cohort, 17 patients (3.3%) were considered poten-
tial therapy switchers, as they discontinued lacosamide but had not
withdrawn from the study at their next visit. Forty-eight patients
(9.7%) in the other AED cohort took lacosamide and were considered
potential therapy switchers.
Pooled safety and efﬁcacy analyses of all patients who received
lacosamide at any time during the study (559/1005, lacosamide cohort
plus therapy switchers in the other AED cohort) did not produceCompleted 12 months
n = 256 (50.1%)
Completed 12 months
n = 256 (51.9%)
Discontinuations: 237 (48.1%)
Due to:
Adverse event: 105 (21.3%)
Lack of efficacy: 42 (8.5%)
Lost to follow-up: 46 (9.3%)
Withdrawn consent: 17 (3.4%)
Other: 27 (5.5%) 
Enrolled Set, N = 1005a  
Treated with adjunctive lacosamide (SS)
n = 511
Potential switcherb: 17 (3.3%)
Monotherapyc: 5 (1.0%)
Discontinuations: 255 (49.9%) 
Due to:
Adverse event: 100 (19.6%)
Lack of efficacy: 70 (13.7%)
Lost to follow-up: 46 (9.0%)
Withdrawn consent: 16 (3.1%) 
Other: 23 (4.5%)
Treated with other adjunctive AED (SS)
n = 493a
Potential switcherd: 48 (9.7%)
Monotherapyc: 31 (6.3%)
Fig. 1. Patient disposition. aOne patient did not meet entry criteria and was later excluded
from the SS. bPatients who discontinued lacosamide and did not discontinue study at next
visit. cPatients treated with one AED for 3 or more consecutive months. dPatients treated
with lacosamide at any time during the study and did not discontinue at the next visit.
AED, antiepileptic drug; SS, safety set.substantial outcome changes compared with those of the lacosamide
cohort.
3.2. Baseline demographics, patient, and epilepsy characteristics
Baseline demographics and patient characteristics were similar
between patients in each cohort (Table 2), although patients in the
lacosamide cohort had a higher median POS frequency per 28 days
and took a greater number of concomitant AEDs (84.9% versus 66.9%
took ≥2) at baseline. Nearly all patients (99.6% in the lacosamide cohort
and 98.4% in the other AED cohort) took one ormore concomitant AEDs
during the study. Most patients (60.5% in the lacosamide cohort and
64.9% in the other AED cohort) had no prior AED use other than the
AEDs taken at baseline. A similar proportion of patients in each cohort
reported a medical history of cardiac or psychiatric disorders (Table 2).
In the SS, 69/1004 (6.9%) patients were ≥65 years of age (24/511
who added lacosamide [4.7%] and 45/493 who added another AED
[9.1%]), and 72/1004 (7.2%) concurrently took antiarrhythmic drugs
(29/511 patients who added lacosamide [5.7%] and 43/493 patients
who added another AED [8.7%]). No patients took a combination of
beta-blocker and calcium antagonist.
3.3. Treatment exposure
For patients who added lacosamide to their baseline treatment reg-
imen, the median duration of exposure was 324.5 days (n = 504). The
modal dose over the treatment period was 200 mg/day (50 mg/day
minimum/700 mg/day maximum, n = 501) and at month 12 was
400 mg/day (50 mg/day minimum/600 mg/day maximum, n = 70).
Five patients took lacosamide asmonotherapy for 3 ormore consecutive
months.
For patients who added an AED other than lacosamide, the median
duration of treatment exposure was 321.0 days (n = 489). Levetirace-
tam was the AED most commonly added to baseline treatment (28.4%).
Others were lamotrigine (14.0%), zonisamide (12.2%), oxcarbazepine
(11.4%), topiramate (10.1%), eslicarbazepine acetate (7.9%), pregabalin
(6.7%), valproate medications (2.8%), and carbamazepine (2.0%); 4.5%
of patients added an alternative AED.
A similar percentage of patients in the lacosamide cohort (33.3%)
and the other AED cohort (29.4%) withdrew from the study because of
lack of efﬁcacy, loss of efﬁcacy, or AEs. A Kaplan–Meier analysis showed
that the adjunctive treatment retention time for the ﬁrst 25% of patients
discontinuing because of lack of efﬁcacy, loss of efﬁcacy, or AEs was
195 days for patients who added lacosamide (95% conﬁdence interval:
148–270) and 190 days for patients who added another AED (95%
conﬁdence interval: 143–267).
3.4. Incidence of predeﬁned CV-related TEAEs
Predeﬁned CV-related TEAEs were experienced by four patients
(0.8%) in each cohort, all of whomwere b65 years of age. All predeﬁned
CV-related TEAEs were mild or moderate in intensity, none were
serious, and none led to discontinuation of adjunctive AED by any
patient (Tables 3 and 4).
Among the four patients in the lacosamide cohort who experienced
a predeﬁned CV-related TEAE, two reported sinus bradycardia, one re-
ported bradycardia, and one reported ﬁrst-degree atrioventricular
(AV) block. One case of sinus bradycardia (55 bpm, reduced from base-
line by 9 bpm) was possibly related to the patient's study medication
(200 mg/day lacosamide adjunctive to lamotrigine and levetiracetam).
The other occurred in a patient taking 50mg/day lacosamide adjunctive
to lamotrigine and was not considered treatment-related (between 56
and 70 bpm throughout enrollment). The case of bradycardia (78 bpm
on the ﬁrst day of treatment) was considered mild in intensity, not
treatment-related, and occurred in a patient taking 100 mg/day
lacosamide adjunctive to levetiracetam, lorazepam, and topiramate.
Table 2
Baseline demographics, patient, and epilepsy characteristics.
Characteristic Lacosamide
n = 511
Other AED
n = 493
Age, mean ± SD, years 39.8 ± 13.58 42.3 ± 15.38
≥65 years, n (%) 24 (4.7) 45 (9.1)
Female, n (%) 266 (52.1) 282 (57.2)
Race, n (%)
White 481 (94.1) 464 (94.1)
Othera 6 (1.2) 7 (1.4)
POS frequency/28 days, median (range)b 6 (0–600) 3.5 (0–1000)
Secondarily generalized seizure frequency
per 28 days, median (range)b
0 (0–100) 0 (0–12)
Seizure frequency/28 days, n (%)b,c
0–2 122 (23.9) 197 (40.0)
N2–5 106 (20.7) 112 (22.7)
N5–10 100 (19.6) 54 (11.0)
N10 161 (31.5) 121 (24.5)
Missing 22 (4.3) 9 (1.8)
AED(s) discontinued prior to baseline, any, n (%) 202 (39.5) 173 (35.1)
In N10% of patients in either cohort
Lamotrigine 69 (13.5) 46 (9.3)
Levetiracetam 68 (13.3) 49 (9.9)
Carbamazepine 66 (12.9) 55 (11.2)
Topiramate 62 (12.1) 33 (6.7)
Number of prior AEDs, n (%)
0 309 (60.5) 320 (64.9)
1 77 (15.1) 83 (16.8)
2 35 (6.8) 36 (7.3)
N2 90 (17.6) 54 (11.0)
Concomitant AED use, n (%) 509 (99.6) 485 (98.4)
In ≥20% patients in either cohort
Levetiracetam 250 (48.9) 196 (39.8)
Lamotrigine 217 (42.5) 167 (33.9)
Carbamazepine 135 (26.4) 112 (22.7)
Oxcarbazepine 123 (24.1) 84 (17.0)
Valproate sodium 100 (19.6) 99 (20.1)
Number of concomitant AEDs, n (%)
0 2 (0.4) 8 (1.6)
1 75 (14.7) 155 (31.4)
2–3 311 (60.9) 259 (52.5)
N3 123 (24.1) 71 (14.4)
Concomitant use of a sodium channel-blocking AED
at any time during treatment, n (%)
384 (75.1) 302 (61.3)
Concomitant antiarrhythmic drug use, n (%)d 29 (5.7) 43 (8.7)
Any concomitant cardiac disorder, n (%) 19 (3.7) 18 (3.7)
Any concomitant psychiatric disorder, n (%) 101 (19.8) 99 (20.1)
AED, antiepileptic drug; POS, partial-onset seizure; SD, standard deviation.
a Race not recorded in France.
b From number of reported seizures during the 2 months prior to baseline.
c Both partial-onset and secondarily generalized seizures.
d World Health Organization Anatomical Therapeutic Chemical codes: C01B
(antiarrhythmics, class I and III), C07 (β-blocking agents), or C08D (selective calcium
channel blockers with direct cardiac effects).
Table 3
Incidence of predeﬁned cardiovascular- and psychiatric-related TEAEs during the ﬁrst 12
months of adjunctive lacosamide or other AED therapy in patients with uncontrolled
partial-onset seizures.
No. of patients (%) Lacosamide
n = 511
Other AED
n = 493
Predeﬁned cardiovascular-related TEAEs
Anya 4 (0.8) 4 (0.8)
Judged to be seriousb 0 0
Leading to discontinuationc 0 0
Judged to be treatment-relatedd 2 (0.4) 1 (0.2)
Patients with relevant medical history 1 (0.2) 2 (0.4)
Sinus bradycardia 2 (0.4) 0
Judged to be treatment-related 1 (0.2) 0
AV block ﬁrst degree 1 (0.2) 0
Judged to be treatment-related 1 (0.2) 0
Bradycardia 1 (0.2) 3 (0.6)
Patients with relevant medical history 1 (0.2) 1 (0.2)
Syncope 0 1 (0.2)
Judged to be treatment-related 0 1 (0.2)
Patients with relevant medical history 0 1 (0.2)
Predeﬁned psychiatric-related TEAEs
Anya 21 (4.1) 27 (5.5)
Judged to be seriousb 4 (0.8) 1 (0.2)
Leading to discontinuationc 2 (0.4) 4 (0.8)
Judged to be treatment-relatedd 11 (2.2) 18 (3.7)
Patients with relevant medical history 7 (1.4) 7 (1.4)
Depression 15 (2.9) 21 (4.3)
Judged to be serious 2 (0.4) 1 (0.2)
Leading to discontinuation 2 (0.4) 3 (0.6)
Judged to be treatment-related 7 (1.4) 12 (2.4)
Patients with relevant medical history 5 (1.0) 4 (0.8)
Depressed mood 4 (0.8) 5 (1.0)
Leading to discontinuation 0 1 (0.2)
Judged to be treatment-related 3 (0.6) 4 (0.8)
Patients with relevant medical history 1 (0.2) 2 (0.4)
Suicide attempt 2 (0.4) 0
Judged to be serious 2 (0.4) 0
Judged to be treatment-related 1 (0.2) 0
Patients with relevant medical history 1 (0.2) 0
Suicidal ideation 1 (0.2) 1 (0.2)
Judged to be treatment-related 0 1 (0.2)
Patients with relevant medical history 1 (0.2) 1 (0.2)
Major depression 0 1 (0.2)
Judged to be treatment-related 0 1 (0.2)
AED, antiepileptic drug; AV, atrioventricular; TEAE, treatment-emergent adverse event.
Coded using Medical Dictionary for Regulatory Activities preferred terms.
a Predeﬁned cardiovascular and psychiatric TEAE terms with no reported incidence are
not shown.
b Serious AE deﬁned as event leading to death, life-threatening adverse experience, ini-
tial or prolonged inpatient hospitalization, signiﬁcant or persistent disability/incapacity,
congenital anomaly, or other important medical event based on the judgment of the
physician.
c Leading to discontinuation of add-on AED treatment.
d Treatment relationship deﬁned as “highly probable”, “probable”, “possible”, or “not
assessable” as judged by the physician.
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ﬁrst-degree AV block was categorized as possibly treatment-related
and occurred in a patient taking 350 mg/day lacosamide adjunctive to
lamotrigine and levetiracetam. None of the TEAEs occurred in patients
taking concomitant antiarrhythmic treatment.
Among the four patients in the other AED cohort who experienced a
predeﬁned CV-related TEAE, three reported bradycardia. One patient
was receiving valproate adjunctive to lamotrigine and was taking anti-
arrhythmic treatment at the time of the bradycardia event (54 bpm
on the ﬁrst day of treatment). This patient had a relevant medical histo-
ry including Factor V Leiden mutation and ongoing hypertension. The
two other patients were taking levetiracetam at the time of bradycardia
onset, one asmonotherapy (52 bpm, reduced from baseline by 13 bpm)
and one adjunctive to lamotrigine (between 48 and 56 bpm at follow-
up visits, reduced from 76 bpm at baseline). In all three cases, bradycar-
dia was considered unlikely to be, or not related to, adjunctive AED
treatment. One other patient reported a TEAE of syncope, which was
possibly related to treatment. This patient was taking phenobarbitaladjunctive to carbamazepine, slow-release valproic acid, clobazam,
and levetiracetam, and had an ongoing medical history of vertigo.3.5. Incidence of predeﬁned psychiatric-related TEAEs
Predeﬁned psychiatric-related TEAEs were experienced by 21
patients (4.1%) in the lacosamide cohort and 27 patients (5.5%) in the
other AED cohort (Table 3). Most of these TEAEs weremild ormoderate
in intensity. The most frequently reported psychiatric-related TEAE in
both cohorts was depression: 15 patients (2.9%)who added lacosamide
and 21 patients (4.3%) who added another AED. In the lacosamide
cohort, all psychiatric-related TEAEs were reported by patients
b65 years of age. Four patients ≥65 years of age in the other AED cohort
reported a psychiatric-related TEAE (Table 4).
Table 4
Incidence of predeﬁned cardiovascular- and psychiatric-related TEAEs of interest during
the ﬁrst 12 months of adjunctive lacosamide or other AED therapy in patients b65 years
and ≥65 years of age with uncontrolled partial-onset seizures.
Age b65 years ≥65 years
No. of patients (%)
Lacosamide
n = 487
Other AED
n = 448
Lacosamide
n = 24
Other AED
n = 45
Cardiovascular-relateda
Any predeﬁned 4 (0.8) 4 (0.9) 0 0
Sinus bradycardia 2 (0.4) 0 0 0
AV block ﬁrst degree 1 (0.2) 0 0 0
Bradycardia 1 (0.2) 3 (0.7) 0 0
Syncope 0 1 (0.2) 0 0
Psychiatric-relateda
Any predeﬁned 21 (4.3) 23 (5.1) 0 4 (8.9)
Depression 15 (3.1) 17 (3.8) 0 4 (8.9)
Depressed mood 4 (0.8) 5 (1.1) 0 0
Suicide attempt 2 (0.4) 0 0 0
Suicidal ideation 1 (0.2) 1 (0.2) 0 0
Major depression 0 0 0 1 (2.2)
AED, antiepileptic drug; AV, atrioventricular; TEAE, treatment-emergent adverse event.
a Predeﬁned cardiovascular- and psychiatric-related TEAE terms with no reported
incidence are not shown.
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Major depression was reported by one patient, 71 years old, in the
other AED cohort. This TEAE was assessed as probably related to leveti-
racetam, which was added to gabapentin therapy. This patient later
discontinued levetiracetam owing to a TEAE of depression.
3.5.2. Depression
Among the 15 patients (2.9%) in the lacosamide cohort who reported
depression, two cases were considered an SAE of moderate intensity.
Neither patient discontinued lacosamide treatment or withdrew from
the study owing to this SAE. One had a history of depression andwas tak-
ing 200mg/day lacosamide adjunctive to carbamazepine and topiramate
at the time of onset, the other had discontinued lacosamide 16 days
previously. Two other patients discontinued lacosamide because of a
TEAE of depression. Seven of the 15 cases of depression were judged
to be related to adjunctive lacosamide treatment. Five of the 15 cases
were reported in patients who had relevant medical history: two of
depression, one of anxiety and depression, one of posttraumatic stress
disorder (PTSD), and one had a familial history of major depressive
disorder. Another patient was taking higher than the approved dosage
of lacosamide at the time of depression onset (700 mg/day), and the
TEAE was not considered related to study treatment.
Of the 21 patients (4.3%) in the other AED cohort who reported a
TEAE of depression, one experienced an SAE of moderate intensity
while taking topiramate as monotherapy. This patient had a medical
history of PTSD and sleep disorder. Depression led to discontinuation
of adjunctive AED treatment in three of the 21 patients. Twelve patients
(2.4%) experienced depression judged to be related to adjunctive AED
treatment. One patient was a therapy switcher; however, the TEAE
resolved shortly after onset, and was classiﬁed as mild and not related
to treatmentwith pregabalin taken adjunctive to lacosamide and leveti-
racetam. Four of the 21 patients had a relevant medical history: two of
depression, one of sleep disorder and PTSD, and one of anxiety and
depression.
In the other AED cohort, four of the patients reporting depression
were ≥65 years of age. Two of the four discontinued adjunctive AED
treatment owing to this TEAE. One other had a medical history of
depression.
3.5.3. Depressed mood
Depressed mood was reported in four patients (0.8%) in the
lacosamide cohort; no cases were considered serious or led to
lacosamide discontinuation. Three of the four reports were consideredpossibly treatment-related, and one of these was in a patient with a his-
tory of depression. Five patients (1.0%) in the other AED cohort reported
a TEAE of depressed mood, of which two cases were considered highly
probably related to study treatment and two were possibly related.
One unrelated case was reported in a patient with a medical history of
insomnia and depression. Depressed mood led to discontinuation of
study treatment in one patient who was taking pregabalin adjunctive
to lamotrigine and had a medical history of insomnia. This TEAE was
considered severe and highly probably related to study treatment. One
patient in the other AED cohort was concomitantly taking lacosamide
at the time of the TEAE onset. This TEAEwas classiﬁed asmoderate inten-
sity and possibly related to study treatment (vigabatrin taken adjunctive
to lacosamide, lamotrigine, levetiracetam, phenobarbital, phenytoin, and
valproate). The TEAE resolved, and the patient continued the study.3.5.4. Predeﬁned psychiatric-related TEAEs relating to suicide
Suicide attempt was reported in two patients (0.4%) who added
lacosamide and in no patients who added another AED. One event was
considered possibly treatment-related and occurred in a patient taking
200 mg/day lacosamide adjunctive to levetiracetam. No medical history
was available for this patient. The other patient had an ongoing medical
history of depression and was taking 450 mg/day lacosamide adjunctive
to carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, phenytoin,
and topiramate. This TEAE was not considered treatment related.
One patient in each cohort reported a TEAE of suicidal ideation. The
patient in the lacosamide cohort had a history of depression and was
taking 300 mg/day lacosamide adjunctive to lamotrigine at the time of
onset. The suicidal ideation was considered unlikely to be related to
lacosamide therapy. The patient from the other AED cohort had a histo-
ry of ongoing suicidal ideation, and the TEAE was considered as proba-
bly related to zonisamide treatment taken adjunctive to carbamazepine.3.6. Other safety outcomes
3.6.1. Overall incidence of TEAEs
The overall incidence of any TEAE is presented in Table 5. Treatment-
emergent adverse events reported by ≥5% of patients in the lacosamide
cohort, and at double the incidence than that reported by patients in the
other AED cohort, were dizziness (21.7% versus 9.1%), diplopia (10.6%
versus 3.7%), nausea (9.6% versus 4.7%), and vertigo (8.8% versus 2.2%).3.6.2. SAEs
Serious adverse events were most commonly associated with the
nervous system (43/78 patients in the lacosamide cohort and 39/64 in
the other AED cohort, Table 5). Convulsion was the most commonly
reported SAE (16 patients [3.1%] who added lacosamide and 17 patients
[3.4%] who added another AED) and was the most common SAE consid-
ered to be treatment-related (6/16 and 3/17 in each cohort, respectively).
Other SAEs occurring in two ormore patients in either cohort and consid-
ered to be treatment-related were grand mal (two patients in the
lacosamide cohort and four patients in the other AED cohort), dizziness
(three and 0), hyponatremia (one and two), and status epilepticus (two
and 0).3.6.3. AEs leading to discontinuation
In total, 100 patients (19.6%) who added lacosamide, and 105 pa-
tients (21.3%) who added another AED, discontinued from the study
owing to AE(s). In the lacosamide cohort, TEAEs led to permanent
discontinuation of lacosamide by 96 patients (18.8%) and temporary
interruption of lacosamide treatment by seven patients (1.4%). In the
other AED cohort, TEAEs led to permanent discontinuation of the
added AED by 94 patients (19.1%) and temporary interruption of the
add-on treatment by three patients (0.6%) (Table 5).
Table 5
Incidence of any TEAE during the ﬁrst 12 months of adjunctive lacosamide or other AED
therapy in patients with uncontrolled partial-onset seizures.
No. of patients (%) Lacosamide
n = 511
Other AED
n= 493
Any TEAE 377 (73.8) 323 (65.5)
Judged to be treatment-relateda 309 (60.5) 258 (52.3)
Most common TEAEsb
Dizziness 111 (21.7) 45 (9.1)
Fatigue 81 (15.9) 62 (12.6)
Headache 56 (11.0) 30 (6.1)
Diplopia 54 (10.6) 18 (3.7)
Nausea 49 (9.6) 23 (4.7)
Vertigo 45 (8.8) 11 (2.2)
Convulsion 36 (7.0) 32 (6.5)
SAEc
Any 78 (15.3) 64 (13.0)
Judged to be treatment-relateda 28 (5.5) 19 (3.9)
Most common SAEsd
Convulsion 16 (3.1) 17 (3.4)
Epilepsy 7 (1.4) 3 (0.6)
Grand mal convulsion 3 (0.6) 11 (2.2)
Partial seizures 1 (0.2) 5 (1.0)
Most common TEAEs leading to permanent
discontinuation of add-on AEDe
Any 96 (18.8) 94 (19.1)
Dizziness 27 (5.3) 8 (1.6)
Fatigue 13 (2.5) 15 (3.0)
Diplopia 11 (2.2) 3 (0.6)
Nausea 10 (2.0) 8 (1.6)
Convulsion 10 (2.0) 8 (1.6)
Deaths 3 (0.6)f 4 (0.8)g
Judged to be treatment-relateda 0 0
AED, antiepileptic drug; SAE, serious adverse event; TEAE, treatment-related adverse
event.
a Treatment relationship deﬁned as “highly probable”, “probable”, “possible”, or “not
assessable”, as judged by the physician.
b TEAEs reported by ≥5% of patients in either treatment cohort.
c Serious TEAE deﬁned as event leading to death, life-threatening adverse experience,
initial or prolonged inpatient hospitalization, signiﬁcant or persistent disability/incapacity,
congenital anomaly, or other important medical event based on the judgment of the
physician.
d In ≥1% of patients in either group.
e In ≥2% patients in either treatment cohort.
f One each of: sudden unexplained/unexpected death in epilepsy, fall, malignant glioma.
g One each of: left ventricular failure, grand mal convulsion, death (no further details),
road trafﬁc accident. Two patients were taking lacosamide at the time of their deaths.
Table 6
Incidence of nonpredeﬁned TEAEs of interest during the ﬁrst 12 months of adjunctive
lacosamide or other AED therapy in patients with uncontrolled partial-onset seizures.
No. of patients (%) Lacosamide Other
AED
n = 511 n = 493
Any nonpredeﬁned TEAEs of interest judged to be treatment-relateda
Cardiac disorders
Angina pectoris 2 (0.4) 0
Palpitations 2 (0.4) 1 (0.2)
Right bundle branch block 1 (0.2) 0
Ventricular extrasystoles 1 (0.2) 0
Left bundle branch block 0 1 (0.2)
Supraventricular extrasystoles 0 1 (0.2)
Atrial ﬁbrillation 0 1 (0.2)
Tachycardia 0 1 (0.2)
ECG abnormalities
QT prolongation 1 (0.2) 1 (0.2)
ST segment elevation 1 (0.2) 0
Most common cognition-related (reported in ≥3 patients in either cohort)b
Memory impairment 11 (2.2) 10 (2.0)
Disturbance in attention 7 (1.4) 7 (1.4)
Cognitive disorder 5 (1.0) 5 (1.0)
Confusional state 3 (0.6) 5 (1.0)
Amnesia 3 (0.6) 1 (0.2)
Any nonpredeﬁned cardiac SAEsc
Atrial ﬂutter 2 (0.4) 0
Atrial ﬁbrillation 1 (0.2) 0
Palpitations 1 (0.2)d 1 (0.2)
Tachycardia 1 (0.2) 0
Acute coronary syndrome 0 1 (0.2)e
Left ventricular failure 0 1 (0.2)d,e
Any nonpredeﬁned cardiac TEAEs leading to study discontinuationf
Palpitations 1 (0.2) 0
Acute coronary syndrome 0 1 (0.2)
Left bundle branch block 0 1 (0.2)g
Left ventricular failure 0 1 (0.2)h
Supraventricular extrasystoles 0 1 (0.2)g
AED, antiepileptic drug; ECG, electrocardiogram; SAE, serious adverse event; TEAE,
treatment-related adverse event.
a Treatment relationship deﬁned as “highly probable”, “probable”, “possible”, or “not
assessable”, as judged by the physician.
b MedDRA 15.0 preferred terms thatwere judged to be associatedwith learning,memory,
perception, or problem solving.
c Serious TEAE deﬁned as event leading to death, life-threatening adverse experience,
initial or prolonged inpatient hospitalization, signiﬁcant or persistent disability/incapacity,
congenital anomaly, or other important medical event based on the judgment of the
physician.
d Conﬁrmed/potential therapy switcher.
e Led to study discontinuation, see section below.
f Any intensity or severity.
g Same patient.
h Due to death. TEAE not considered treatment-related.
40 B.J. Steinhoff et al. / Epilepsy & Behavior 58 (2016) 35–433.6.4. Deaths
During the study, seven patients died (Table 5): three who added
lacosamide and four who added another AED. Two of the patients in
the other AED cohort were considered therapy switchers, and were
taking lacosamide at the time of their deaths. None of the deaths were
thought to be linked to the added AED therapy (lacosamide or other
AED).3.6.5. Other cardiac-, ECG-, and cognition-related TEAEs (not predeﬁned)
Cardiac-related TEAEs (cardiac disorders system organ class,
MedDRA v15.0) that were judged to be treatment-related and were
not part of the predeﬁned analysis are presented in Table 6.
Five patients in the lacosamide cohort and three patients in the other
AED cohort experienced cardiac-related SAEs which were not part of
the predeﬁned analysis (Table 6). One was considered treatment-
related (palpitations in a potential therapy switcher, taking anunknown
dose of lacosamide adjunctive to carbamazepine, phenobarbital,
and zonisamide), and two led to study discontinuation (one of left
ventricular failure in a therapy switcher, and one of acute coronary
syndrome). Cardiac TEAEs which were not predeﬁned or considered
serious caused one additional patient in each cohort to discontinue
the study (Table 6).Electrocardiogram data were available for less than ~20% of patients
who attended each recommended visit (including patients who were
discontinuing at that visit). ECG abnormalities that were reported as
TEAEs and judged to be treatment-related are presented in Table 6.
There were no reports of PR interval prolongation or other ECG abnor-
malities that led to study discontinuation.
Cognition-related TEAEs (those considered to be associated with
learning, memory, perception or problem solving) that were judged to
be treatment-related and reported in ≥3 patients of either cohort are
presented in Table 6. All others were reported in b3 patients overall:
disorientation, hypoesthesia, hallucination, sedation (all in 2/1004),
altered state of consciousness, delirium, depressed level of conscious-
ness, dysesthesia, dysgeusia, and impaired reasoning (all in 1/1004).
Ten patients (2.0%) who added lacosamide and eleven patients (2.2%)
who added another AED discontinued from the study due to any
cognition-related TEAE.
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No clinically relevant changes from baseline in vital signs or body
weight were observed in patients of either cohort.
3.7. Seizure control
After 3 months of treatment, the median percent change in POS
frequency from 2-month retrospective baseline was−46.2% in patients
who added lacosamide and−58.0% in patients who added other AEDs.
After 12 months of treatment, median changes were −67.1% and
−86.0%, respectively. Furthermore, 53.8% (242/450 at 3 months) to
62.9% (161/256 at 12 months) of patients who added lacosamide
showed improvement on the Clinical Global Impression of Change
questionnaire compared with 52.2% (221/423 at 3 months) to 69.8%
(173/248 at 12 months) of patients who added another AED.
4. Discussion
This was a comprehensive observational PASS in patients initiating
adjunctive lacosamide or another approved AED in real-life medical
practice. A low incidence of predeﬁned CV- and psychiatric-related
TEAEs was revealed in both treatment cohorts.
Epilepsy has associated CV risks [41], with AED use bringing
additional concerns due to the inhibitory actions of these drugs on
neuronal conductance. This leads to a pragmatic approach to epilepsy
treatment in patientswith cardiac risk factors [15,42,43]. Clinical studies
have shown a small, dose-related increase in PR interval associatedwith
lacosamide use [11–13,18], with a magnitude similar to that observed
with other AEDs including carbamazepine, eslicarbazepine acetate,
and lamotrigine [14,44–48]. Despite these ﬁndings, cases of serious
cardiac conduction abnormalities during lacosamide use are rare. The
LACO-IV real-world observational safety study reported one case of PR
prolongation and one case of third-degree AV block among 98 patients
with diverse medical histories who were treated in the emergency
department setting with intravenous lacosamide for status epilepticus
or acute repetitive seizures [18]. Both patients had ischemic cardiomy-
opathy and continued, or returned to, lacosamide therapy after the
event. The safety of lacosamide is further supported by a comprehensive
analysis of the cardiac safety data pooled from 1304 patients who took
part in the registration trials for lacosamide in the treatment of POS.
This analysis showed no speciﬁc cardiac risks, aside from the small,
dose-related increase in PR interval, with no evident symptomatic
consequence [19]. Furthermore, a positively controlled QTc trial in
healthy volunteers showed no detrimental effect associated with
lacosamide use at approved dosages [20].
Several case reports have described cardiac conduction abnormalities
in patients with epilepsy receiving lacosamide therapy. Four cases were
in patients taking lacosamide as recommended under the current local
marketing authorization for the treatment of POS: one experienced bra-
dycardia and second-degree AV block [21], one experienced bradycardia
[9], one experienced ventricular tachycardia during a cardiac stress test
[22], while the other experienced atrial ﬁbrillation [23]. Two additional
cases were in patients with POS taking lacosamide at a higher than ap-
proved dosage: one experienced atrial ﬂutter/ﬁbrillation (600 mg/day)
[24], while the other experienced sinus node dysfunction (500mg/day)
[25]. Three additional patients experienced third-degree AV blockwhile
receiving lacosamide for the treatment of nonconvulsive status
epilepticus—all were N65 years of age [18,26,27]. Another case was in
a child with subclinical seizures, hypoplastic left-heart syndrome, and
previously well-controlled atrial tachycardia, who experienced atrial
tachycardia coinciding with lacosamide treatment [28]. Among
these 10 cases, ﬁve were in patients also taking traditional sodium chan-
nel-blocking AEDs, including carbamazepine [9,21,22,25] and lamotrigine
[22,24]. All patients completely recovered after discontinuing lacosamide.
The published case reports highlight rare CV-related AEs occurring
in patients taking lacosamide in real-world clinical practice, oftenalongside numerous comorbidities. Case reports should be viewed in
the context of the estimated 544,257 patient years of experience with
lacosamide, accrued during the clinical development program and
from pharmacovigilance data [UCB Pharma data on ﬁle. Lacosamide De-
velopment SafetyUpdate Report Number 4 for the Period 01-Sept.-2013
to 31-Aug.-2014]. In the current study, speciﬁc CV-related TEAEs (both
predeﬁned and nonpredeﬁned) were observed in three or fewer
patients (b1%) in each cohort during the ﬁrst year of adjunctive AED
therapy, demonstrating a low overall incidence of CV-related events in
routine clinical practice. These results suggest that lacosamide use is
unlikely to augment the risk of experiencing a CV-related AE compared
with other adjunctive AEDs approved for the treatment of POS.
Patients with epilepsy are also known to be at increased risk of
psychiatric-relateddisorders [33–35]. Several AEDshave knownpsychi-
atric and behavioral side effects in patients with epilepsy, possibly
representing a drug class effect [44,46–53]. Depression was the most
common predeﬁned psychiatric-related TEAE reported in this study
for patients in both treatment cohorts. The proportion of patients
reporting predeﬁned psychiatric-related TEAEs was numerically higher
in patients adding an AED other than lacosamide (5.5% versus 4.1% in
patients who added lacosamide), but few cases were considered to be
related to treatment in either cohort. This suggests that lacosamide
use is unlikely to augment the risk of experiencing a relevant psychiatric
AE comparedwith other adjunctive AEDs approved for the treatment of
POS.
Based on the compulsory class product labeling, suicidality is a
recognized risk deﬁned in the product characteristics of AEDs, including
lacosamide [1–3,40]. In the current study, the numbers of suicidal
ideation reportswere similar amongpatients in both treatment cohorts.
Suicide attempt was the only predeﬁned psychiatric TEAE reported
with a higher incidence in the lacosamide cohort than in the other
AED cohort (two patients versus 0). One patient had a relevant medical
history, and neither discontinued lacosamide treatment because of this
TEAE. Furthermore, the overall death rate in this noninterventional
postauthorization study (1 per 100 patient years) was in the lower
range of those observed in other safety studies [46,47].
Additional subgroup analyses exploring the incidence of predeﬁned
CV- and psychiatric-related events in patients ≥65 years of age, and
in those taking antiarrhythmic drugs, were limited by low patient
numbers. Although no clear conclusions can be drawn, these analyses
did not suggest any speciﬁc vulnerabilities for these populations.
Furthermore, outcomes were not altered when therapy switchers were
discounted (patients who either added or discontinued lacosamide
after initial cohort assignment but did not discontinue the study at the
next visit).
Incidences of all TEAEs in patients who added lacosamide were
comparable to those observed in the registration trials for use in the
treatment of POS,with themost common being dizziness, fatigue, head-
ache, diplopia, nausea, and vertigo [5–7]. In the current study, many of
these TEAEs occurred at double the incidence in patients adding
lacosamide as compared with patients adding other AEDs. This is likely
attributable to the heterogeneous nature of the added AEDs in the other
AED cohort (including both sodium channel-blocking AEDs and
nonsodiumchannel-blocking AEDswith diversemechanisms of action).
A broader TEAE proﬁle could therefore be anticipated among patients in
the other AED cohort owing to the increased diversity of treatment
regimens taken.
Overall patient retention was similar in both cohorts, with ~49%
discontinuing from each during theﬁrst year of adjunctive AED therapy.
This percentage may be reﬂective of the ﬂexible, noninterventional na-
ture of the study design. A slightly higher proportion of patients (13.7%)
who added lacosamide discontinued therapy owing to lack of efﬁcacy,
compared with those who added another AED (8.5%). In part, this may
be explained by the observation that patients in the lacosamide cohort
enrolled with more severe, treatment-refractory epilepsy, as indicated
by a greater number of seizures during the baseline period (6.0 versus
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lower median percentage reductions in POS frequency per 28 days
from baseline achieved after 12 months of treatment (−67.1% and
−86.0%, respectively). Such an imbalance between the two cohorts
was difﬁcult to avoid given the noninterventional, nonrandomized
study design, where treatment allocation was determined by the
investigator's judgment, representing decisions taken in real-life clinical
practice. These decisions may also have been inﬂuenced by the
physician's limited experiences of lacosamide, which was relatively
newly approved at the time of the study.
Limitations of this study include the noninterventional, non-
randomized design, which led to baseline imbalances between the
treatment cohorts. Additionally, the ﬂexible nature of the dosing
regimens prevented direct comparison of outcomes between cohorts,
or attribution of TEAEs to speciﬁc adjunctive AEDs or dosages. In partic-
ular, adaptable dosing and the ability to add or discontinue concomitant
AEDs at any time during the study allowed for therapy switching,
making it challenging to evaluate TEAEs in terms of the prescribed
AED's mode of action (e.g., sodium channel blocking versus nonsodium
channel blocking). However, use of individually optimized regimens
for each patient permits a real-world assessment of lacosamide
and avoids the more artiﬁcial ﬁxed-dose approach used in clinical
trials. The current study included a relatively large patient cohort,
facilitating sensitive detection of TEAEs, but is limited to the ﬁrst
12 months of exposure. Open-label extension trials of lacosamide
have followed patients for up to 8 years and have not reported
the emergence of CV or psychiatric risks associated with longer-term
treatment [11,13].4.1. Conclusions
Patients with POS, uncontrolled by their current AED regimen and
who added lacosamide or another AED to current therapy, reported
few CV- or psychiatric-related AEs during the ﬁrst 12 months of
treatment. Furthermore, no speciﬁc safety concerns were associated
with adjunctive lacosamide versus other adjunctive AED use.Acknowledgments
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